NCT00111826View on ClinicalTrials.gov

SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes

PHASE3TerminatedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

December 31, 2005

Conditions
Peripheral Arterial DiseaseArterial Occlusive DiseasesIntermittent Claudication
Interventions
DEVICE

Celacade™ system

Sponsors

Lead Sponsor

Vasogen
All Listed Sponsors
lead

Vasogen

INDUSTRY

NCT00111826 - SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes | Biotech Hunter | Biotech Hunter